Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next ...

Hansa Biopharma announces positive results from NICE-01 trial of next generation IgG-cleaving molecule, HNSA-5487: Lund, Sweden Tuesday, October 8, 2024, 11:00 Hrs [IST] Hansa Bio ...

In neuroscience, antibodies are essential for investigating neurodegenerative disorders, facilitating early diagnosis and ...

New research on Marburg virus survivors identifies a key immunogen in the virus's wing domain, offering a promising target ...

"At-home lab testing for IgG (short for the responsive antibodies called immunoglobulin G) reactivity can be a great way for ...

A study led by researchers at the University of Rochester Medical Center found that breast milk provides protection against ...

In AAV, a variety of ANCA syndromes is linked to the same ANCA IgG with diverse concurrent immune events responsible for modifying inflammatory injury.

Researchers reported that levels of anti-BP180 autoantibodies may be the best marker for monitoring the disease activity of ...

SAN DIEGO, CA, USA I October 8, 2024 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...

Injectable Drug Market. The global injectable drug market is poised for significant growth, with an estimated valuation of ...

These DIY kits are a $5 billion industry. We report on the pros, the cons, and the ones to avoid at all costs.